Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

23/09/2020

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant.

Tel: 07989 595237

ADDRESS

Registered Address:

1 Market Hill, Calne, Wiltshire SN11 0BT

Company Number: 12023096

OPENING HOURS

Monday - Friday: 9:00am - 5:00pm   

SUBSCRIBE TO JOIN OUR MAILING LIST

© 2019 by The Governance Academy